等待开盘 05-21 09:30:00 美东时间
+1.390
+0.39%
The acquisition of Everest Colombia strengthens AIG's presence in the Latin America region and supports the company's strategy to drive premium growth."This acquisition reinforces AIG's commitment to our Latin America
05-19 20:57
今日重点评级关注:HC Wainwright & Co.:维持Autolus Therapeutics"买入"评级,目标价从9美元升至10美元;Maxim Group:维持Rezolute"买入"评级,目标价从4美元升至10美元
05-15 10:49
今日重点评级关注:Needham:维持Artiva Biotherapeutics"买入"评级,目标价从18美元升至41美元;HC Wainwright & Co.:维持SAB Biotherapeutics"买入"评级,目标价从7美元升至10美元
05-13 11:46
Citigroup analyst Matthew Heimermann maintains Everest Group (NYSE:EG) with a Neutral and raises the price target from $342 to $395.
05-13 02:49
今日重点评级关注:Citizens:维持BioCryst制药"跑赢大市"评级,目标价从25美元升至28美元;富国银行:维持曼恩凯德生物医疗"超配"评级,目标价从8美元升至10美元
05-08 12:05
今日重点评级关注:Citizens:维持Avalo Therapeutics"跑赢大市"评级,目标价从52美元升至62美元;BTIG:维持Avalo Therapeutics"买入"评级,目标价从40美元升至58美元
05-07 12:37
今日重点评级关注:Canaccord Genuity:维持Sagimet Biosciences"买入"评级,目标价从28美元升至49美元;HC Wainwright & Co.:维持Fate Therapeutics"买入"评级,目标价从5美元升至7美元
05-05 11:40
UBS analyst Brian Meredith maintains Everest Group (NYSE:EG) with a Neutral and raises the price target from $370 to $374.
05-05 04:28
华盛资讯4月30日讯,Everest Group, Ltd.公布2026财年Q1业绩,公司Q1营收36.02亿美元,同比下降18.0%,归母净利润6.53亿美元,同比增长211.0%。
04-30 06:22
Everest Group (NYSE:EG) reported quarterly earnings of $16.08 per share which beat the analyst consensus estimate of $14.05 by 14.45 percent. This is a 149.3 percent increase over earnings of $6.45 per share from the
04-30 04:25